Integral Diagnostics Ltd (ASX: IDX) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Integral Diagnostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $522.97 million
P/E Ratio 20.85
Dividend Yield 2.71%
Shares Outstanding 233.47 million
Earnings per share 0.106
Dividend per share 0.05
Year To Date Return 18.90%
Earnings Yield 4.80%
Franking 100%
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Integral Diagnostics Ltd (ASX: IDX)
    Latest News

    Rede arrow on a stock market chart going down.
    Share Fallers

    Why ASX, Coronado, Graincorp, and Integral Diagnostics shares are dropping today

    These ASX shares are missing out on the market rally today....

    Read more »

    A man looks surprised as a woman whispers in his ear.
    Broker Notes

    2 ASX shares to buy now at bargain prices that you've forgotten about

    There are many cheap stocks currently out there to consider. Here's a pair you might not have on your radar.

    Read more »

    Two children sit amid a tangle of wires at a desk looking sad and despondent.
    52-Week Lows

    Is opportunity knocking? 2 ASX All Ordinaries shares hitting 52-week lows

    Catch a falling knife? Or opportunity knocking?

    Read more »

    Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
    Earnings Results

    Integral Diagnostics (ASX:IDX) share price on ice after trio of big announcements

    Here's the latest on the ASX diagnostics company amid its half-year results.

    Read more »

    two children squat down in the dirt with gardening tools and a watering can wearing denim overalls and smiling very sweetly.
    Ask a Fund Manager

    2 ASX shares to buy for dirt cheap right now: expert

    Ask A Fund Manager: Forager Funds Management's Gaston Amoros names a pair of stocks that the market is unfairly punishing.

    Read more »

    A surprised and curious male investor drinks black coffee while reading the latest news on rising ASX shares in the newspaper
    Broker Notes

    Here are the latest broker updates from Macquarie. It's not all pretty for ASX shares.

    Macquarie is the latest broker to release its buy and sell tips in early 2022.

    Read more »

    Broker Notes

    Top brokers name 3 ASX shares to buy next week

    Brokers are feeling positive about these ASX shares...

    Read more »

    Thumbs down Facebook icon over dark screen
    Share Fallers

    Why Integral Diagnostics, Mayne Pharma, NEXTDC, & Wesfarmers are dropping

    These ASX shares are ending the week in the red...

    Read more »

    falling healthcare asx share price represented by doctor grimacing at x-ray
    Earnings Results

    Integral Diagnostics (ASX:IDX) share price slides 14% on FY21 earnings

    The market has reacted negatively to Integral Diagnostics' FY21 results.

    Read more »

    share price gaining
    Share Market News

    Which ASX shares are ending the week as the biggest movers today?

    The ASX 300 has spent the day in the red...

    Read more »

    shadow of a man looking out a window with arrows signifying falling share price
    Share Fallers

    Why Chalice Mining, GUD, Integral Diagnostics, & PointsBet are dropping

    These ASX shares are in the red today...

    Read more »

    chart showing an increasing share price
    Dividend Investing

    2 growing ASX dividend shares analysts rate as buys

    These dividend shares are growing at a solid rate...

    Read more »

    Frequently Asked Questions

    Yes, Integral Diagnostics historically pays two fully franked dividends a year.

    Integral Diagnostics generally pays its shareholder dividends in April and October.

    Integral Diagnostics Ltd listed on the ASX on 21 October 2015.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    29 Feb 2024 $0.0250 100.00% Interim 02 Apr 2024
    31 Aug 2023 $0.0350 100.00% Final 04 Oct 2023
    02 Mar 2023 $0.0250 100.00% Interim 04 Apr 2023
    01 Sep 2022 $0.0300 100.00% Final 05 Oct 2022
    01 Mar 2022 $0.0400 100.00% Interim 04 Apr 2022
    02 Sep 2021 $0.0700 100.00% Final 06 Oct 2021
    01 Mar 2021 $0.0550 100.00% Interim 06 Apr 2021
    28 Aug 2020 $0.0400 100.00% Final 01 Oct 2020
    28 Feb 2020 $0.0550 100.00% Interim 07 Apr 2020
    30 Aug 2019 $0.0500 100.00% Final 02 Oct 2019
    01 Mar 2019 $0.0500 100.00% Interim 02 Apr 2019
    31 Aug 2018 $0.0400 100.00% Final 04 Oct 2018
    31 Jan 2018 $0.0400 100.00% Interim 05 Mar 2018
    31 Aug 2017 $0.0000 100.00% Final 04 Oct 2017
    28 Feb 2017 $0.0300 100.00% Interim 30 Mar 2017
    31 Aug 2016 $0.0400 100.00% Final 04 Oct 2016

    IDX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Integral Diagnostics Ltd

    Integral Diagnostics Ltd (ASX: IDX) is an Australian healthcare services company providing medical imaging services. 

    The group operates in a single business providing diagnostic imaging to general practitioners, medical specialists, and allied health professionals and their patients. 

    The company operates more than 90 radiology clinics across Australia and New Zealand. It is also a joint venture partner in Medx, expanding its services to the United Kingdom and Ireland.

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    01 Dec 2023 Andrew Fay Buy 15,000 $25,575
    On-market trade.
    01 Dec 2023 Ian Kadish Buy 20,000 $35,050
    On-market trade.
    30 Nov 2023 Ian Kadish Issued 248,970 $441,921
    Issue of securities. 858,583 - Rights
    30 Nov 2023 Ingrid Player Buy 35,000 $60,725
    On-market trade.
    20 Sep 2023 Ian Kadish Issued 26,035 $75,241
    Issue of securities. 6,09,613 Performance Rights
    28 Aug 2023 Ian Kadish Expiry 435,572 $1,354,628
    As advised by the company. Lapse of rights, 583,578 Rights
    04 Apr 2023 John Atkin Issued 1,680 $4,647
    Dividend Reinvestment Plan (DRP).

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Andrew James Fay Non-Executive Director Jul 2022
    Mr Fay brings to the Board over 30 years of experience in funds and investment management, including Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management (Australia) Limited. He also held several other senior investment roles at Deutsche Asset Management and previously at AMP Capital. From 1998 to 2006, he was a member of the Investment Board Committee of the Financial Services Council. Andrew is an experienced company director across ASX listed, private and regulated entities and accordingly brings to the Board skills in financial and risk management, capital markets, executive remuneration frameworks, strategy, investment, and corporate governance. Specifically, he has sector experience and expertise in financial services, including investment, funds, property and infrastructure management. He is also Member of the Risk and Compliance Committee.
    Dr Jacqueline Milne Executive Director Nov 2019
    Dr Milne Dr Milne is a full-time permanently employed radiologist of the Company based in Queensland and is therefore considered by the Board to be a Non-Independent Executive Director. While Dr Milne is not an independent director by virtue of her employment, she is independent of senior management and her responsibilities do not extend to the day-to-day management of the Company. She is Member of the Integral Clinical Leadership Committee.
    Ms Raelene Margaret Murphy Non-Executive Director Oct 2017
    Ms Murphy has over 30 years of experience in strategic, financial, and operational leadership in both industry and professional advisory, after beginning her career in audit. She was formerly a Partner in a national accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career, she specialized in operational and financial restructuring, with a particular emphasis on merger and acquisition integration across a range of public and private companies. Raelene is a Fellow of Chartered Accountants Australia and New Zealand and has extensive experience as Chair of Audit and Risk Committees for ASX listed companies. She is Chair of the Risk and Compliance Committee.
    Ms Ingrid Anne Player Non-Executive Director Aug 2023
    Ms Player has more than 20 years experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms Player was Group Executive Legal, Governance and Sustainability at Healthscope, one of Australias largest private healthcare providers. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specialising in corporate law, M&A and capital markets. She brings to the Board experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She currently serves as a Non-Executive Director of Cleanaway Management Ltd (ASX:CWY), Cogstate Ltd (ASX:CGS), Epworth Foundation and HealthShare Victoria
    Mr James Tobias Hall Non-Executive Director Sep 2023
    Mr Hall has experience in Australia and New Zealand and is an experienced Board and Committee Chair. Mr Hall was Group CEO of St Vincents Health Australia from 2014 to 2022, He has also overseen multisite, for-profit generating businesses at both board and executive levels in employment services, early learning services and aged care. His experience in M&A includes the acquisition of ABC Childcare from administration. Mr Hall is currently non-executive Chair of Sana Health Group, non-executive Chair of For Purpose Aged Care, non-executive Director of UNICEF Australia, a trustee of Yajilarra (a philanthropic foundation) and advisory board member for Fujitsu Australia and New Zealand. His former non-executive roles include Chair of ASX listed Sterihealth, board member of Goodstart Early Learning, board member of Working Links (a UK based for profit employment service) and two New Zealand based community built regional hospitals.
    Dr Ian Kadish Chief Executive OfficerManaging Director May 2017
    Mr Kadish began his career as a medical doctor in Johannesburg, South Africa. Ian was helpful in growing the group from five hospitals with a market capitalisation of $60m, to 119 hospitals and a market capitalisation of $3bn. Since migrating to Australia in 2006, Dr Kadish's roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group and CEO of Laverty Pathology. He is also a Director of the Australian Diagnostic Imaging Association (ADIA). He is also Member of the Integral Clinical Leadership Committee.
    Ms Nikki Dalla Valle Company Secretary Dec 2023
    Craig White Chief Financial Officer
    Paul McCrow Chief Operating Officer
    Nikki Dalla Valle Company Secretary
    Jacqueline Milne Radiologist Executive Director
    Nazar Bokani Radiologist Executive Director

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 41,305,475 17.73%
    Citicorp Nominees Pty Limited 37,720,613 16.19%
    J P Morgan Nominees Australia Pty Limited 30,949,506 13.28%
    National Nominees Limited 12,416,583 5.33%
    BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <DRP A/C> 4,309,344 1.85%
    BNP Paribas Noms Pty Ltd <DRP> 3,943,475 1.69%
    Hsbc Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 3,469,048 1.49%
    New Imaging Pty Ltd <New Imaging A/C> 3,389,045 1.45%
    Washington H Soul Pattinson And Company Limited 3,290,936 1.41%
    Citicorp Nominees Pty Limited <Colonial First State INV A/C> 3,276,722 1.41%
    Lethean Holdings Pty Ltd <Howitt No 8 A/C> 2,944,760 1.26%
    J A Mullins Pty Ltd <James A Mullins Family A/C> 2,616,051 1.12%
    Firbar Pty Ltd <The Howitt No 4 A/C> 2,357,230 1.01%
    Lockwood Ridge Pty Ltd <The AJ French Family A/C> 2,177,058 0.93%
    Mittal Holdings Pty Ltd <Howitt No 12 A/C> 2,085,907 0.90%
    Mr Vincent Michael O'sullivan <O'sullivan A/C> 2,059,000 0.88%
    Wyndham Salter Pty Ltd <The Howitt No 10 A/C> 1,862,947 0.80%
    Masfen Securities Limited 1,710,000 0.73%
    Netwealth Investments Limited <Wrap Services A/C> 1,605,935 0.69%
    BNP Paribas Noms (NZ) Ltd <DRP> 1,509,566 0.65%